FR2906533B1 - Procede de generation d'anticorps actifs contre un antigene de resistance,anticorps obtenus par ledit procede et leurs utilisations - Google Patents

Procede de generation d'anticorps actifs contre un antigene de resistance,anticorps obtenus par ledit procede et leurs utilisations

Info

Publication number
FR2906533B1
FR2906533B1 FR0608514A FR0608514A FR2906533B1 FR 2906533 B1 FR2906533 B1 FR 2906533B1 FR 0608514 A FR0608514 A FR 0608514A FR 0608514 A FR0608514 A FR 0608514A FR 2906533 B1 FR2906533 B1 FR 2906533B1
Authority
FR
France
Prior art keywords
generating active
antibodies
antibodies against
antigen
resistance
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR0608514A
Other languages
English (en)
French (fr)
Other versions
FR2906533A1 (fr
Inventor
Liliane Goetsch
Alexandra Jouhanneaud
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pierre Fabre Medicament SA
Original Assignee
Pierre Fabre Medicament SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to FR0608514A priority Critical patent/FR2906533B1/fr
Application filed by Pierre Fabre Medicament SA filed Critical Pierre Fabre Medicament SA
Priority to MX2009003245A priority patent/MX2009003245A/es
Priority to JP2009529701A priority patent/JP5774276B2/ja
Priority to KR1020097008469A priority patent/KR101504770B1/ko
Priority to CN200780035523.8A priority patent/CN101516394B/zh
Priority to RU2009114682/10A priority patent/RU2515904C2/ru
Priority to HK09110874.1A priority patent/HK1131063B/xx
Priority to EP07820636.4A priority patent/EP2081592B1/en
Priority to NZ576420A priority patent/NZ576420A/en
Priority to AU2007312437A priority patent/AU2007312437C1/en
Priority to PCT/EP2007/060243 priority patent/WO2008046724A1/en
Priority to BRPI0717246-0A2A priority patent/BRPI0717246A2/pt
Priority to UAA200904020A priority patent/UA102812C2/ru
Priority to EP12159077.2A priority patent/EP2494984B1/en
Priority to EP12159086.3A priority patent/EP2497491B1/en
Priority to CA002663561A priority patent/CA2663561A1/en
Priority to EP12159083.0A priority patent/EP2491945B9/en
Priority to US12/442,918 priority patent/US8241646B2/en
Priority to ARP070104320A priority patent/AR063061A1/es
Priority to TW096136193A priority patent/TWI516276B/zh
Publication of FR2906533A1 publication Critical patent/FR2906533A1/fr
Priority to IL197790A priority patent/IL197790A/en
Priority to TN2009000102A priority patent/TN2009000102A1/fr
Priority to MA31800A priority patent/MA30954B1/fr
Priority to ZA200902697A priority patent/ZA200902697B/xx
Priority to NO20091613A priority patent/NO20091613L/no
Priority to US13/544,672 priority patent/US8808667B2/en
Application granted granted Critical
Publication of FR2906533B1 publication Critical patent/FR2906533B1/fr
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5152—Tumor cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Developmental Biology & Embryology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
FR0608514A 2006-09-28 2006-09-28 Procede de generation d'anticorps actifs contre un antigene de resistance,anticorps obtenus par ledit procede et leurs utilisations Expired - Fee Related FR2906533B1 (fr)

Priority Applications (26)

Application Number Priority Date Filing Date Title
FR0608514A FR2906533B1 (fr) 2006-09-28 2006-09-28 Procede de generation d'anticorps actifs contre un antigene de resistance,anticorps obtenus par ledit procede et leurs utilisations
CA002663561A CA2663561A1 (en) 2006-09-28 2007-09-27 Method for generating active antibodies against a resistance antigen, antibodies obtained by said method and their uses
KR1020097008469A KR101504770B1 (ko) 2006-09-28 2007-09-27 내성 항원에 대항하는 활성 항체의 생산 방법, 상기 방법에 의해 생산된 항체 및 이의 용도
CN200780035523.8A CN101516394B (zh) 2006-09-28 2007-09-27 制备抗耐药性抗原的活性抗体的方法、所述方法获得的抗体及其用途
RU2009114682/10A RU2515904C2 (ru) 2006-09-28 2007-09-27 Способ генерирования активных антител к антигену устойчивости, антитела, полученные этим способом, и их применения
HK09110874.1A HK1131063B (en) 2006-09-28 2007-09-27 Method for generating active antibodies against a resistance antigen, antibodies obtained by said method and their uses
EP07820636.4A EP2081592B1 (en) 2006-09-28 2007-09-27 Method for generating active antibodies against a resistance antigen, antibodies obtained by said method and their uses
NZ576420A NZ576420A (en) 2006-09-28 2007-09-27 Method for generating active antibodies against a resistance antigen, antibodies obtained by said method and their uses
AU2007312437A AU2007312437C1 (en) 2006-09-28 2007-09-27 Method for generating active antibodies against a resistance antigen, antibodies obtained by said method and their uses
PCT/EP2007/060243 WO2008046724A1 (en) 2006-09-28 2007-09-27 Method for generating active antibodies against a resistance antigen, antibodies obtained by said method and their uses
BRPI0717246-0A2A BRPI0717246A2 (pt) 2006-09-28 2007-09-27 Método para gerar anticorpos ativos contra um antígeno de resistência, anticorpos obtidos pelo dito método e seus usos
UAA200904020A UA102812C2 (ru) 2006-09-28 2007-09-27 Способ генерирования активных антител к антигену устойчивости, антитела, полученные этим способом, и их применение
EP12159077.2A EP2494984B1 (en) 2006-09-28 2007-09-27 Method for generating active antibodies against a resistance antigen, antibodies obtained by said method and their uses
EP12159086.3A EP2497491B1 (en) 2006-09-28 2007-09-27 Method for generating active antibodies against a resistance antigen, antibodies obtained by said method and their uses
MX2009003245A MX2009003245A (es) 2006-09-28 2007-09-27 Metodo para generar anticuerpos contra un antigeno resistente, anticuerpos obtenidos por el metodo y sus usos.
EP12159083.0A EP2491945B9 (en) 2006-09-28 2007-09-27 Method for generating active antibodies against a resistance antigen, antibodies obtained by said method and their uses
JP2009529701A JP5774276B2 (ja) 2006-09-28 2007-09-27 耐性抗原に対する活性抗体を作製する方法、その方法により得られる抗体およびそれらの使用
US12/442,918 US8241646B2 (en) 2006-09-28 2007-09-27 Method for generating active antibodies against a resistance antigen, antibodies obtained by said method and their uses
ARP070104320A AR063061A1 (es) 2006-09-28 2007-09-28 Metodo de generacion de anticuerpos activos contra un antigeno de resistencia, anticuerpos obtenidos por dicho metodo y sus utilizaciones
TW096136193A TWI516276B (zh) 2006-09-28 2007-09-28 產生對抗一抗性抗原之活性抗體的方法、由該方法所獲得之抗體及其用途
IL197790A IL197790A (en) 2006-09-28 2009-03-24 METHOD FOR PRODUCING ANTI-RESISTANT ANTI-RESISTANT ANTIBODY, ANTIBODY PRODUCED AND USED ANTIBODIES
TN2009000102A TN2009000102A1 (en) 2006-09-28 2009-03-26 Method for generating active antibodies against a resistance antigen, antibodies obtained by said method and their uses
MA31800A MA30954B1 (fr) 2006-09-28 2009-04-17 Procede de generation d'anticorps actifs contre un antigene de resistance, anticorps obtenus par ce procede et utilisations de ces anticorps
ZA200902697A ZA200902697B (en) 2006-09-28 2009-04-20 Method for generating active antibodies against a resistance antigen, antibodies obtained by said method and their uses
NO20091613A NO20091613L (no) 2006-09-28 2009-04-22 Fremgangsmate for generering av aktive antistoffer mot et resistansantigen, antistoffer fremskaffet ved nevnte fremgangsmate og deres anvendelser
US13/544,672 US8808667B2 (en) 2006-09-28 2012-07-09 Method for generating active antibodies against a resistance antigen, antibodies obtained by said method and their uses

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0608514A FR2906533B1 (fr) 2006-09-28 2006-09-28 Procede de generation d'anticorps actifs contre un antigene de resistance,anticorps obtenus par ledit procede et leurs utilisations

Publications (2)

Publication Number Publication Date
FR2906533A1 FR2906533A1 (fr) 2008-04-04
FR2906533B1 true FR2906533B1 (fr) 2013-02-22

Family

ID=38164542

Family Applications (1)

Application Number Title Priority Date Filing Date
FR0608514A Expired - Fee Related FR2906533B1 (fr) 2006-09-28 2006-09-28 Procede de generation d'anticorps actifs contre un antigene de resistance,anticorps obtenus par ledit procede et leurs utilisations

Country Status (21)

Country Link
US (2) US8241646B2 (https=)
EP (4) EP2497491B1 (https=)
JP (1) JP5774276B2 (https=)
KR (1) KR101504770B1 (https=)
CN (1) CN101516394B (https=)
AR (1) AR063061A1 (https=)
AU (1) AU2007312437C1 (https=)
BR (1) BRPI0717246A2 (https=)
CA (1) CA2663561A1 (https=)
FR (1) FR2906533B1 (https=)
IL (1) IL197790A (https=)
MA (1) MA30954B1 (https=)
MX (1) MX2009003245A (https=)
NO (1) NO20091613L (https=)
NZ (1) NZ576420A (https=)
RU (1) RU2515904C2 (https=)
TN (1) TN2009000102A1 (https=)
TW (1) TWI516276B (https=)
UA (1) UA102812C2 (https=)
WO (1) WO2008046724A1 (https=)
ZA (1) ZA200902697B (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7241444B2 (en) * 2002-01-18 2007-07-10 Pierre Fabre Medicament Anti-IGF-IR antibodies and uses thereof
CU23736A1 (es) * 2009-05-04 2011-11-15 Centro Inmunologia Molecular Anticuerpos que reconocen sulfatidos y proteoglicanos sulfatados y su uso
WO2011004899A1 (en) * 2009-07-06 2011-01-13 Takeda Pharmaceutical Company Limited Cancerous disease modifying antibodies
US20120282211A1 (en) * 2009-11-24 2012-11-08 Carnegie Mellon University Antibodies and conjugates for modulators of angiogenesis
EP2635602B1 (en) 2010-11-03 2016-09-07 Argen-X Nv Anti c-met antibodies
US9255595B2 (en) * 2011-04-29 2016-02-09 Bae Systems Information And Electronic Systems Integration Inc. Optical dome bezel
US9926364B2 (en) 2011-11-03 2018-03-27 Argen-X N.V. Chimeric human-llama antigens and methods of use
US9657098B2 (en) 2013-03-15 2017-05-23 Intrinsic Lifesciences, Llc Anti-hepcidin antibodies and uses thereof
TW201613615A (en) 2014-06-30 2016-04-16 Academia Sinica Antagonists for interleukin-17 receptor B (IL-17RB) and its ligand IL-17B for cancer therapy
AU2015321462B2 (en) 2014-09-22 2020-04-30 Intrinsic Lifesciences Llc Humanized anti-hepcidin antibodies and uses thereof
AR105553A1 (es) * 2015-04-27 2017-10-18 Pf Medicament Anticuerpo del receptor del factor 1 del crecimiento similar a insulina (igf-1r) y su utilización para diagnosticar cáncer
TWI740824B (zh) * 2015-04-27 2021-10-01 法商皮爾法伯製藥公司 新穎的ｉｇｆ－１ｒ抗體及其用於癌症診斷之用途（一）
EP3334757A4 (en) * 2015-08-14 2019-04-03 Merck Sharp & Dohme Corp. ANTI-Tigit ANTIBODY
US10981991B2 (en) * 2015-09-29 2021-04-20 Shanghai Zhangjiang Biotechnology Co., Ltd. PD-1 antibodies and uses thereof
GB2547179A (en) * 2015-10-26 2017-08-16 Quethera Ltd Genetic construct
WO2025111382A2 (en) * 2023-11-21 2025-05-30 Board Of Regents, The University Of Texas System Anti-lamp5 antibodies, engineered immune cells expressing anti-lamp5 antibodies, and uses thereof

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS6261596A (ja) * 1985-09-11 1987-03-18 Japan Found Cancer Res 薬剤耐性癌に関するモノクロ−ナル抗体およびその製造
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
GB8924581D0 (en) 1989-11-01 1989-12-20 Pa Consulting Services Bleaching of hair
EP1690934A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
GB9014932D0 (en) 1990-07-05 1990-08-22 Celltech Ltd Recombinant dna product and method
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
JPH05244982A (ja) 1991-12-06 1993-09-24 Sumitomo Chem Co Ltd 擬人化ｂ−ｂ１０
KR950700061A (ko) * 1992-02-06 1995-01-16 스티븐 엘. 네스비트 테트라아릴에틸렌에 의한 다중 약물 내성의 역전(reversal of multi -drug resistance by tetraarylethylenes)
IT1257893B (it) * 1992-06-17 1996-02-16 Ist Superiore Sanita Anticorpi monoclonali che riconoscono un epitopo della p-glicoproteina umana.
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
US5503984A (en) * 1993-04-13 1996-04-02 Health Research, Inc. Hybridoma producing monoclonal antibody F4 which specifically binds to multidrug resistant P-glycoprotein and assays for detection of P-glycoprotein
WO1999066027A1 (en) * 1998-06-15 1999-12-23 The Research Foundation Of State University Of New York Monoclonal antibodies that recognize antigens associated with tumor metastasis
US7303760B2 (en) 1999-04-23 2007-12-04 Alza Corporation Method for treating multi-drug resistant tumors
DE60312639T2 (de) 2002-01-18 2007-11-29 Pierre Fabre Médicament Antikörper gegen igf-ir und ihre verwendungen
US20040121965A1 (en) 2002-09-20 2004-06-24 Wyeth Holdings Corporation Method of treating resistant tumors
WO2005035721A2 (en) * 2003-10-08 2005-04-21 Ebioscience Native immunoglobulin binding reagents and methods for making and using same
WO2005077385A2 (en) 2004-02-18 2005-08-25 Gpc Biotech Ag Methods for treating resistant or refractory tumors
EP1742060A1 (en) * 2005-01-24 2007-01-10 DIGILAB BioVisioN GmbH TIF1-beta peptides and nucleic acids for diagnosis and therapy of cancer and colorectal cancerous disorders.

Also Published As

Publication number Publication date
ZA200902697B (en) 2010-04-28
US8808667B2 (en) 2014-08-19
CN101516394B (zh) 2014-07-30
WO2008046724A1 (en) 2008-04-24
EP2491945B1 (en) 2016-12-07
NO20091613L (no) 2009-06-26
CA2663561A1 (en) 2008-04-24
TN2009000102A1 (en) 2010-08-19
AR063061A1 (es) 2008-12-23
EP2497491B1 (en) 2017-03-01
US20100146650A1 (en) 2010-06-10
EP2491945A1 (en) 2012-08-29
UA102812C2 (ru) 2013-08-27
KR101504770B1 (ko) 2015-03-20
TW200822934A (en) 2008-06-01
MX2009003245A (es) 2009-07-07
NZ576420A (en) 2012-05-25
JP5774276B2 (ja) 2015-09-09
EP2494984B1 (en) 2017-01-04
FR2906533A1 (fr) 2008-04-04
AU2007312437B2 (en) 2014-01-23
RU2009114682A (ru) 2010-11-20
EP2497491A1 (en) 2012-09-12
MA30954B1 (fr) 2009-12-01
IL197790A (en) 2016-10-31
BRPI0717246A2 (pt) 2013-10-08
AU2007312437C1 (en) 2014-04-10
EP2491945B9 (en) 2017-03-08
HK1131063A1 (en) 2010-01-15
US20130028835A1 (en) 2013-01-31
KR20090057469A (ko) 2009-06-05
JP2010504743A (ja) 2010-02-18
EP2081592A1 (en) 2009-07-29
RU2515904C2 (ru) 2014-05-20
TWI516276B (zh) 2016-01-11
EP2081592B1 (en) 2016-01-13
EP2494984A1 (en) 2012-09-05
US8241646B2 (en) 2012-08-14
AU2007312437A1 (en) 2008-04-24
IL197790A0 (en) 2011-08-01
CN101516394A (zh) 2009-08-26

Similar Documents

Publication Publication Date Title
FR2906533B1 (fr) Procede de generation d'anticorps actifs contre un antigene de resistance,anticorps obtenus par ledit procede et leurs utilisations
EP2313504A4 (en) RADIOISOTOPMARKED ANTI-CDH3 ANTIBODIES AND USES THEREOF
EP1948798A4 (en) Anti-alpha2 integrin antibodies and their uses
EP1812062A4 (en) ANTI-ADDL ANTIBODIES AND ITS USES
EP2068887A4 (en) SP35 ANTIBODY AND ITS USE
EP1836294A4 (en) ANTI-IL-12 ANTIBODIES, EPITOPES, COMPOSITIONS, METHODS AND USES
DK3276349T3 (da) Haptener, haptenkonjugater, sammensætninger deraf og fremgangsmåder til fremstilling og anvendelse deraf
BRPI0918471A2 (pt) sistema para armazenamento e dosagem de amônia, método de armazenamento e dosagem de amônia a partir de um material de armazenamento de amônia sólida.
BRPI0812657A2 (pt) "sistema para gerar, detectar e interpretar sinais acústicos em um sistema de poço e método para detectar e interpretar sinais acústicos em um sistema de poço"
EP1728801A4 (en) SUBTYP OF A HUMANIZED ANTIBODY AGAINST THE INTERLEUKIN-6 RECEPTOR
MX2010006395A (es) Formulacion de anticuerpos.
EP1976046A4 (en) FUEL CELL REMOVER, PROCESS FOR ITS MANUFACTURE AND FUEL CELL WITH SEPARATOR
EP2233501A4 (en) HUMANIZED MONOCLONAL ANTI-CD34 ANTIBODIES AND THEIR PREPARATION AND APPLICATIONS
DK1939214T3 (da) Celler og metodik til at generere ikke-segmenterede negativstrengede RNA-vira
EP2061808A4 (en) INFLUENZA ANTIBODIES, COMPOSITIONS AND RELATED METHODS
EP2245156A4 (en) HUMANIZED ANTI-9 INTEGRIN ANTIBODIES AND USES THEREOF
FR2924440B1 (fr) Nouveau procede de generation et de criblage d'une banque d'anticorps
ES1059765Y (es) Dispositivo para generacion de energia.
WO2007051169A3 (en) Use of b cell expansion agents in generating antibodies
WO2008060817A3 (en) Exothermic personal lubricant
BRPI0910367A2 (pt) "método para geração de uma planta transformada, planta transformada e planta transformada com um vetor"
NL1031104A1 (nl) Systeem en werkwijze voor lithografie in halfgeleider productie.
ITTO20050330A1 (it) Dispositivo trasduttore fluidodinamico per lo sfruttamento dell'energia cinetica di veicoli terrestri.
BRPI0910357A2 (pt) "método para geração de uma planta transformada, planta transformada e planta transformada com um vetor"
FR2931481B1 (fr) Anticorps specifique de la lysine propionylee/butyrylee, son procede d'obtention et ses applications

Legal Events

Date Code Title Description
PLFP Fee payment

Year of fee payment: 11

ST Notification of lapse

Effective date: 20180531